188 related articles for article (PubMed ID: 31520575)
1. Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.
Copeland BT; Du J; Pal SK; Jones JO
Mol Oncol; 2019 Dec; 13(12):2616-2632. PubMed ID: 31520575
[TBL] [Abstract][Full Text] [Related]
2. The androgen receptor malignancy shift in prostate cancer.
Copeland BT; Pal SK; Bolton EC; Jones JO
Prostate; 2018 May; 78(7):521-531. PubMed ID: 29473182
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
4. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ
Cancer Res; 2005 Aug; 65(15):6640-50. PubMed ID: 16061644
[TBL] [Abstract][Full Text] [Related]
6. PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells.
Ikezoe T; Chen SS; Yang Y; Heber D; Taguchi H; Koeffler HP
Int J Oncol; 2003 Nov; 23(5):1461-70. PubMed ID: 14532991
[TBL] [Abstract][Full Text] [Related]
7. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
8. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
9. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
10. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.
Yang X; Guo Z; Sun F; Li W; Alfano A; Shimelis H; Chen M; Brodie AMH; Chen H; Xiao Z; Veenstra TD; Qiu Y
J Biol Chem; 2011 Oct; 286(41):36152-36160. PubMed ID: 21878636
[TBL] [Abstract][Full Text] [Related]
11. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation.
Alimirah F; Chen J; Basrawala Z; Xin H; Choubey D
FEBS Lett; 2006 Apr; 580(9):2294-300. PubMed ID: 16580667
[TBL] [Abstract][Full Text] [Related]
12. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
13. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
[TBL] [Abstract][Full Text] [Related]
14. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
15. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
[TBL] [Abstract][Full Text] [Related]
17. PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer.
Buchanan G; Craft PS; Yang M; Cheong A; Prescott J; Jia L; Coetzee GA; Tilley WD
Prostate; 2004 Sep; 60(4):352-66. PubMed ID: 15264248
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3.
Tilley WD; Bentel JM; Aspinall JO; Hall RE; Horsfall DJ
Steroids; 1995 Jan; 60(1):180-6. PubMed ID: 7792809
[TBL] [Abstract][Full Text] [Related]
20. ELF3 is a repressor of androgen receptor action in prostate cancer cells.
Shatnawi A; Norris JD; Chaveroux C; Jasper JS; Sherk AB; McDonnell DP; Giguère V
Oncogene; 2014 Feb; 33(7):862-71. PubMed ID: 23435425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
